Price regulation and relative delays in generic drug adoption.

Increasing the adoption of generic drugs has the potential to improve static efficiency in a health system without harming pharmaceutical innovation. However, very little is known about the timing of generic adoption and diffusion. No prior study has empirically examined the differential launch times of generics across a comprehensive set of markets, or more specifically the delays in country specific adoption of generics relative to the first country of (generic) adoption. Drawing on data containing significant country and product variation across a lengthy time period (1999-2008), we use duration analysis to examine relative delays, across countries, in the adoption of generic drugs. Our results suggest that price regulation has a significant effect on reducing the time to launch of generics, with faster adoption in higher priced markets. The latter result is dependent on the degree of competition and the expected market size.

[1]  L. Garattini,et al.  Off-patent drugs in Italy , 2006, The European Journal of Health Economics.

[2]  M. Furukawa,et al.  Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets , 2011 .

[3]  M. Ekelund,et al.  Pharmaceutical Pricing in a Regulated Market , 2003, Review of Economics and Statistics.

[4]  H. Grabowski,et al.  Generic Competition in the US Pharmaceutical Industry , 2006 .

[5]  T. Aronsson,et al.  The Impact of Generic Drug Competition on Brand Name Market Shares – Evidence from Micro Data , 2001 .

[6]  Andrea Coscelli,et al.  The Importance of Doctors' and Patients' Preferences in the Prescription Decision , 2003 .

[7]  Joan Costa-Font,et al.  The Pharmaceutical Market Regulation in Spain: Is Drug Cost-Containment Under Question? , 2005 .

[8]  J. Lexchin.  Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices , 2006, Canadian Medical Association Journal.

[9]  S. Simoens,et al.  Sustaining Generic Medicines Markets in Europe , 2006 .

[10]  Toshiaki Iizuka.  Generic Entry in a Regulated Pharmaceutical Market , 2008 .

[11]  Henry G. Grabowski,et al.  Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act , 1992, The Journal of Law and Economics.

[12]  A. Anis,et al.  Lowering Generic Drug Prices: Less Regulation Equals More Competition , 2003, Medical care.

[13]  G. Perry.  The European Generic Pharmaceutical Market in Review: 2006 and Beyond , 2006 .

[14]  Richard E. Caves,et al.  Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry , 1991 .

[15]  Bae Jp.  Drug patent expirations and the speed of generic entry. , 1997 .

[16]  D. Salkever,et al.  "Generic Entry and the Pricing of Pharmaceuticals" , 1995 .

[17]  J. Hellerstein,et al.  The importance of the physician in the generic versus trade-name prescription decision. , 1998, The Rand journal of economics.

[18]  Tracy L. Regan.  Generic entry, price competition, and market segmentation in the prescription drug market , 2008 .

[19]  Massimo Riccaboni,et al.  Dynamic competition in pharmaceuticals , 2004, The European Journal of Health Economics, formerly: HEPAC.

[20]  Zvi Griliches,et al.  Generics and New Goods in Pharmaceutical Price Indexes , 1993 .

[21]  N. Rudholm.  Entry and the Number of Firms in the Swedish Pharmaceuticals Market , 2001 .

[22]  Li-Wei Chao,et al.  Does Regulation Drive Out Competition in Pharmaceutical Markets?* , 2000, The Journal of Law and Economics.

[23]  A. Hollis.  The Anti-Competitive Effects of Brand-Controlled "Pseudo- Generics" in the Canadian Pharmaceutical Market , 2003 .

[24]  Generic Drug Industry Dynamics , 2002 .

[25]  Fiona M. Scott Morton.  Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry , 2000 .

[26]  S. Simoens,et al.  Generic Medicine Pricing Policies in Europe: Current Status and Impact , 2010, Pharmaceuticals.

[27]  Joan Costa-Font,et al.  Competition in Off-Patent Drug Markets: Issues, Regulation and Evidence , 2008 .

[28]  Frederic M. Scherer,et al.  Pricing, Profits, and Technological Progress in the Pharmaceutical Industry , 1993 .

[29]  F. Morton,et al.  Entry decisions in the generic pharmaceutical industry. , 1999, The Rand journal of economics.

[30]  Joan Costa-Font,et al.  Brand loyalty, patients and limited generic medicines uptake. , 2014, Health policy.

[31]  John Hudson,et al.  Generic take-up in the pharmaceutical market following patent expiry A multi-country study , 2000 .

[32]  Richard E. Caves,et al.  Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals , 1988, The Journal of Law and Economics.

[33]  Pricing, Patent Loss and the Market for Pharmaceuticals , 1991 .

[34]  R. Abbott.  Logistic regression in survival analysis. , 1985, American journal of epidemiology.

[35]  P. Danzon,et al.  Cross-national price differences for pharmaceuticals: how large, and why? , 2000, Journal of health economics.